Biotechnology - Pixuvri

Filter

Current filters:

Pixuvri

Popular Filters

Cell Thera’s NHL drug Pixuvri gets backing from UK’s NICE

27-02-2014

US biotech firm Cell Therapeutics has received positive news from the UK’s drugs watchdog for use of…

BiotechnologyCell TherapeuticsNorthern EuropeOncologyPixuvriPricingRegulationUK

Cell Therapeutics to reacquire rights to two anti-cancer compounds

13-01-2014

US biotech firm Cell Therapeutics says it has reached an agreement with partner Novartis to reacquire…

BiotechnologyCell TherapeuticsLicensingNovartisOncologyOpaxioPixuvri

UK’s NICE says yes to Cell Thera’s non-Hodgkin’s lymphoma drug Pixuvri

UK’s NICE says yes to Cell Thera’s non-Hodgkin’s lymphoma drug Pixuvri

31-12-2013

US biotech firm Cell Therapeutics’ Pixuvri (pixantrone), a treatment for an aggressive type of cancer…

BiotechnologyCell TherapeuticsEuropeOncologyPixuvriPricingRegulation

Cell Therapeutics reaches price deal with German insurer GKV-SV on Pixuvri

Cell Therapeutics reaches price deal with German insurer GKV-SV on Pixuvri

04-12-2013

US biotech firm Cell Therapeutics has concluded an agreement with the Germany’s National Association…

BiotechnologyCell TherapeuticsOncologyPixuvriPricingRare diseases

Germany's G-BA issues final assessment for Cell Thera's Pixuvri

21-05-2013

USA-based Cell Therapeutics (Nasdaq: CTIC) says that Germany's Federal Joint Committee (G-BA) has issued…

BiotechnologyCell TherapeuticsEuropeOncologyPharmaceuticalPixuvriPricingRegulation

Cell Therapeutics initiates launch of Pixuvri in Europe

12-09-2012

Following the European approval of the drug this spring (The Pharma Letter May 14), US biotech firm Cell…

BiotechnologyCell TherapeuticsEuropeMarkets & MarketingOncologyPixuvriRare diseases

Cell Therapeutics prepares for Pixuvri launch; posts 2nd-qtr results

01-08-2012

US biotech firm Cell Therapeutics (Nasdaq: CTIC) yesterday reported second-quarter 2012 financial results…

BiotechnologyCell TherapeuticsFinancialMarkets & MarketingOncologypacritinibPixuvriRare diseasesResearchtosedostat

Cell Therapeutics prepares for EU launch of Pixuvri

21-06-2012

USA-based biotech company Cell Therapeutics (Nasdaq and MTA: CTIC) said yesterday that it is re-aligning…

BiotechnologyCell TherapeuticsEuropeMarkets & MarketingOncologypacritinibPixuvriResearchtostedostat

Cell Therapeutics' Pixuvri cleared in EU for NHL

14-05-2012

US biotech firm Cell Therapeutics (Nasdaq and MTA: CTIC) last week received conditional marketing authorization…

BiotechnologyCell TherapeuticsEuropeOncologyPharmaceuticalPixuvriRegulation

Cell Therapeutics updates on Pixuvri

30-01-2012

Seattle, USA-based Cell Therapeutics (Nasdaq and MTA: CTIC) says that it has voluntarily withdrawn its…

BiotechnologyCell TherapeuticsNorth AmericaOncologyPixuvriRegulation

Company Spotlight

ImmunoGen

ImmunoGen

Back to top